Jpmorgan Chase & CO Atea Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 46,216 shares of AVIR stock, worth $154,823. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,216

Previous 103,256 55.24%

Holding current value

$154,823

Previous $417,000 63.55%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$3.31 - $4.04 $188,802 - $230,441	-57,040 Reduced 55.24%	46,216 $152,000
Q1 2024 May 10, 2024	BUY	$3.09 - $4.56 $107,624 - $158,824	34,830 Added 50.9%	103,256 $417,000
Q4 2023 Feb 12, 2024	BUY	$2.8 - $3.35 $81 - $97	29 Added 0.04%	68,426 $208,000
Q3 2023 Nov 14, 2023	BUY	$3.0 - $3.79 $16,500 - $20,845	5,500 Added 8.74%	68,397 $205,000
Q2 2023 Aug 11, 2023	BUY	$3.21 - $5.06 $2,195 - $3,461	684 Added 1.1%	62,897 $235,000
Q1 2023 May 18, 2023	BUY	$3.0 - $4.97 $175,356 - $290,506	58,452 Added 1554.16%	62,213 $208,000
Q1 2023 May 11, 2023	SELL	$3.0 - $4.97 $618,771 - $1.03 Million	-206,257 Reduced 98.21%	3,761 $12,000
Q4 2022 Feb 13, 2023	BUY	$4.35 - $6.17 $108,636 - $154,089	24,974 Added 13.5%	210,018 $1.01 Million
Q3 2022 Nov 14, 2022	BUY	$5.49 - $8.79 $771,010 - $1.23 Million	140,439 Added 314.85%	185,044 $1.05 Million
Q2 2022 Aug 11, 2022	SELL	$5.33 - $8.18 $932,723 - $1.43 Million	-174,995 Reduced 79.69%	44,605 $317,000
Q1 2022 May 11, 2022	BUY	$5.5 - $9.19 $955,240 - $1.6 Million	173,680 Added 378.22%	219,600 $1.59 Million
Q4 2021 Feb 10, 2022	BUY	$7.67 - $44.59 $15,876 - $92,301	2,070 Added 4.72%	45,920 $411,000
Q3 2021 Nov 12, 2021	BUY	$21.33 - $35.06 $935,320 - $1.54 Million	43,850 New	43,850 $1.54 Million

Others Institutions Holding AVIR

# of Institutions

111

Shares Held

51.5M

Call Options Held

71.8K

Put Options Held

318K

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $279M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Atea Pharmaceuticals, Inc. Transaction History